EUS-guided pancreatic diagnosis and beyond. Highlights from the "2011 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. January 20-22, 2011.

Endoscopic ultrasound-guided fine needle aspiration: from the past to the future. Endosc Ultrasound (2013) 1.13

Automatic tracking of arbitrarily shaped implanted markers in kilovoltage projection images: a feasibility study. Med Phys (2014) 0.89

Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. J Gastrointest Oncol (2016) 0.75

Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39

Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys (2013) 1.59

Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57

Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55

Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44

Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43

Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30

Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29

Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28

Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol (2013) 1.22

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18

Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17

Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07

Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 1.06

Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06

The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol (2011) 1.05

First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 1.05

Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04

Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03

Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol (2015) 1.03

Radiation therapy and esophageal cancer. Cancer Control (2013) 1.03

Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02

Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02

Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02

Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02

Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00

Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00

Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99

Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98

Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. Gastrointest Cancer Res (2013) 0.97

Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96

IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96

Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96

Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95

Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP (2010) 0.94

Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP (2008) 0.94

Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93

Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control (2008) 0.93

Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93

FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91

Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90

The multidisciplinary management of rectal cancer. Surg Clin North Am (2009) 0.90

Sexual function in colorectal cancer survivors. Cancer Control (2010) 0.90

Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89

Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89

Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89

Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89

Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89

First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.88

Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88

Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87

Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer (2014) 0.87

Early detection of pancreatic cancer. JOP (2012) 0.87

Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87

Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs (2009) 0.87

Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87

Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis. Cancer (2013) 0.87

Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87

Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.86

Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.86

Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86

Quality of life in patients with pancreatic cancer. JOP (2012) 0.86

Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.86

Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86

Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86

Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85

Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85

Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85

Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85

Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85

Initial experience from a large referral center with robotic-assisted Ivor Lewis esophagogastrectomy for oncologic purposes. Surg Endosc (2013) 0.85

Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.85

Management of borderline resectable pancreatic adenocarcinoma. JOP (2012) 0.84

Improved survival in patients with lymph node-positive gastric cancer who received preoperative radiation: an analysis of the Surveillance, Epidemiology, and End Results database. Cancer (2011) 0.84

Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.84

Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84

The impact of body mass index on esophageal cancer. Cancer Control (2013) 0.84

Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84

Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84

Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.84

Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.84

Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis. J Gastrointest Surg (2013) 0.84

Advancements in the management of pancreatic cancer. JOP (2009) 0.83

Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83

Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP (2010) 0.83

Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.83

First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83

Adjuvant therapy for pancreatic cancer. JOP (2014) 0.83

Diabetes and pancreatic cancer. JOP (2014) 0.83

PARP-inhibitors in BRCA-associated pancreatic cancer. JOP (2014) 0.83

Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP (2007) 0.82

Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer. Ther Adv Med Oncol (2012) 0.82

Biomarkers in neuroendocrine tumors. JOP (2013) 0.82

Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP (2009) 0.82

The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82

Locally advanced pancreatic adenocarcinoma: update and progress. JOP (2012) 0.82

Role of anticoagulation in the management of pancreatic cancer. JOP (2009) 0.82